- Langley, R. G. B., Krueger, G. G. & Griffiths, C. E. M. (2005):-Psoriasis: epidemiology, clinical features, and quality of life. Annals of the rheumatic diseases, 64(suppl 2), ii18-ii23.
- Griffiths, C.E. & Barker, J.N. (2007):- Pathogenesis and clinical features of psoriasis. The Lancet, 370(9583), 263-271.
- Schons, K.R.R., Knob, C.F., Murussi, N., Beber, A.A.C., Neumaier, W. & Monticielo, O.A. (2014):- Nail psoriasis; a review of the liter ature. Anais brasileiros de dermatologia, 89(2), 312-317.
- Krueger, J.G., & Bowcock, A. (2005):- Psoriasis pathophysiology; current concepts of pathogenesis. Annals of the rheumatic diseases, 64(suppl 2), ii30-ii36.
- Bai, F., Zheng, W., Dong, Y., Wang, J., Garstka, M. A., Li , R. & Ma, H. (2018):- Serum levels of adipokines and cytokines in psoriasis patients; a systematic review and meta-analysis. Oncotarget, 9 (1), 1266.
- Fukuhara, A., Matsuda, M., Nishizawa, M., Segawa, K., Tanaka, M., Kishimoto, K. & Watanabe, E. (2005):- Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science, 307(5708), 426-430.
- Moschen, A. R., Kaser, A., Enrich, B., Mosheimer, B., Theurl, M., Niederegger, H. & Tilg, H. (2007):- Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. The Journal of Immunology, 178(3), 1748-1758.
- Stofkova, A. (2010):- Resistin and visfatin; regulators of insulin sensitivity, inflammation and immunity. Endocrine regulations, 44 (1), 25-36.
- Okan, G., Baki, A. M., Yorulmaz, E., Dogru‐Abbasoglu, S. & Vural, P. (2016):- Serum visfatin, fetuin‐A, and pentraxin 3 levels in patients with psoriasis and their relation to disease severity. Journal of clinical laboratory analysis, 30(4), 284-289.
- Christophers, E. (2007):- Comorbidities in psoriasis. Clinic s in dermatology, 25(6), 529-534.
- Verghese B, Bhatnagar S, Tanwar R, Bhattacharjee J (2011):- Serum cytokine profile in psoriasis-a case-control study in a tertiary care hospital from northern India. Indian J Clin Biochem; 26(4): 373-377.
- Antuna-Puente, B., Feve, B., Fellahi, S. & Bastard, J. P. (2008):- Adipokines; the missing link between insulin resistance and obesity. Diabetes & metabolism, 34(1), 2-11.
- Ala-Houhala MJ, Karppinen T, Vahavihu K, et al. (2014):- Narrow-band Ultraviolet B Treatment Boosts Serum 25-hydroxy vitamin D in Patients with Psoriasis on Oral Vitamin D Supplementation. Acta Derm Venereol; 94: 146–151.
- Berndt, J., Kloting, N., Kralisch, S., Kovacs, P., Fasshauer, M., Schon, M. R. & Bluher, M. (2005):- Plasma visfatin concentrations and fat depot–specific mRNA expression in humans. Diabetes, 54(10), 2911-2916.
- Friebe, D., Neef, M., Kratzsch, J., Erbs, S., Dittrich, K., Garten, A. & Bluher, M. (2011):- Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase(NAMPT)/pre-B cell colony (PBEF)/visfatin linking obesity and inflammation in humans. Diabetologia, 54(5), 1200-1211.
- Komine, M., Karakawa, M., Takekoshi, T., Sakurai, N., Minatani, Y., Mitsui, H. & Tamaki, K. (2007):- Early inflammatory changes in the “perilesional skin” of psoriatic plaques: is there interaction between dendritic cells and keratinocytes? Journal of investigative dermatology, 127(8), 1915-1922.
- Parisi, R., Symmons, D. P., Griffiths, C. E. & Ashcroft, D. M. (2013):- Global epidemiology of psoriasis; a systematic review of incidence and prevalence. Journal of Investigative Dermatology, 133(2), 377-385.
- Ismail, S. A. & Mohamed, S. A. (2012):- Serum levels of visfatin and omentin‐1 in patients with psoriasis and their relation to disease severity. British Journal of Dermatology, 167(2), 436-439.
- Lopez‐Estebaranz, J. L., Sanchez‐Carazo, J. L. & Sulleiro, S. (2016):- Effect of a family history of psoriasis and age on comorbidities and quality of life in patients with moderate to severe psoriasis: Results from the ARIZONA study. The Journal of dermatology, 43(4), 395-401.
- Abd-ElRaheem, T., Ali, S. A., Mohamed, S. R. & Mohamed, H. A. (2019):- Visfatin, Omentin-1 and lipid profile in patients with psoriasis their relation and Disease to severity. Fayoum University Medical Journal, 2(1), 32-36.
- Badran, F. K., Genedy, R. M., Swelem, R. S. & Al-Rawi, M. Z. (2014):- Evaluation of serum level of visfatin among psoriatic patients. Egyptian Journal of Dermatology and Venerology, 34(2), 107.
- Yan, W., Huang, Y., Yan, X. & Zhou, Y. (2011):- Clinical significance of serum visfatin and high mobility groupbox1 (HMGB1) in psoriasis vulgaris. Chinese J. Clin, 5, 9-15.
- Sereflican, B., Goksugur, N., Bugdayci, G., Polat, M. & Haydar Parlak, A. (2016):- Serum visfatin, adiponectin, and tumor necrosis factor alpha (TNF-α) levels in patients with psoriasis and their correlation with disease severity. Acta Dermatovenerologica Croatica, 24(1), 13-13.
- Bozkurt, N. M., Yildirim, M., Ceyhan, A. M., Kara, Y. & Vural, H. (2010):- Psoriasisli hastalarda serum visfatin duzeylerinin arastirilmasi. TURKDERM-Deri Hastaliklari ve Frengi Arsivi, 44(1), 15-18.
- Chyl-Surdacka, K. M., Bartosinska, J., Kowal, M., Przepiorka-Kosinska, J., Krasowska, D. & Chodorowska, G. (2020):- Assessment of visfatin concentrations in the serum of male psoriatic patients in relation to metabolic abnormalities. Advances in Clinical and Experimental Medicine, 29(1), 79-84.
- Abd Elfattah, W. M. (2017):- Serum level of Visfatin in Psoriasis and its Relation to Disease Severity. The Egyptian Journal of Hospital Medicine, 69(1), 1558-1562.
|